[Influence of the double antiplatelet therapy on patency of the occluded artery after acute @entity583 with XXXX ].

@entity1 @entity662 @entity1397 @entity1347 @entity117 @entity1188 @entity951 @entity583
BACKGROUND/AIM: Most @entity1 with acute @entity583 with @entity1347 ( @entity1347 ) are still treated with pharmacological reperfusion, which is not always successful. That is the reason for searching possibilities for a better success of reperfusion with adding new antiplatelet drugs. The aim of this study was to investigate weather addition of @entity1397 as a second antiplatelet drug, improves the patency of the @entity1188 after @entity1347 . METHODS: We prospectively enrolled 65 @entity1 , 29-72 years old, hospitalized due to the first @entity1347 within 6 hours after the on-set of a @entity662 . They were treated with a fibrinolytic agent (streptokinase or tissue plasminogen activator--tPA), @entity117 , and low molecular heparin (enoxaparin). A group of 50 @entity1 , beside this therapy, received @entity1397 . Coronary angiography was performed between 5th and 10th day of hospitalization to assess for late patency of the @entity1188 . @entity1188 was considered as patent if thrombolysis in @entity583 (TIMI) flow grade was 2 or 3, and as occluded if TIMI flow grade was 0 or 1. RESULTS: In the group of @entity1 who received double antiplatelet therapy ( @entity117 and @entity1397 ), @entity1188 was occluded in 3 cases (6%); in the group of @entity1 without @entity1397 , @entity1188 was occluded in 4 @entity1 (26.7%),p < 0.05. There were less frequency of @entity951 (6% vs 13.3%), and rarer necessity for rescue percutaneous coronary intervention (4% vs. 13.3%) in the first group, but without statistical significance. CONCLUSION: Adding of @entity1397 to the standard reperfusion pharmacotherapy, as a second antiplatelet drug, increases the number of @entity1 with patent @entity1188 and the success of reperfusion.
